背景:作为2004年发现的FAD(黄素腺嘌呤二核苷酸)依赖性组蛋白去甲基酶,据报道LSD1(赖氨酸特异性去甲基酶1)在多种肿瘤中过表达,调节与癌症发展相关的靶基因转录。因此,LSD1靶向抑制剂可能代表抗癌药物发现的新见解。由于这些原因,制药行业和学术界的研究人员一直在积极寻求LSD1抑制剂,以寻求新的抗癌药物。
目的:本文总结了近5年LSD1抑制剂的相关专利,以期为研究人员开发LSD1新的LSD1调节剂提供参考。
方法:本综述收集了自2016年以来专利中公开的LSD1抑制剂。专利检索的主要方式是Espacenet®,谷歌专利,和CNKI。
结果:这篇综述涵盖了近五年来与LSD1抑制剂相关的数十项专利。化合物结构主要分为TCP(转氨环丙胺)衍生物,咪唑衍生物,嘧啶衍生物,和其他天然产物和肽。同时,还描述了已经进入临床阶段的化合物。
结论:这些专利中的大多数化合物已经过LSD1和多细胞系的活性分析,在体外和体内表现出良好的抗肿瘤活性。这些专利展示了LSD1抑制剂的结构多样性和天然产物作为新型LSD1抑制剂的潜力。
BACKGROUND: As a FAD (Flavin Adenine Dinucleotide) - dependent histone demethylase discovered in 2004, LSD1 (lysine specific demethylase 1) was reported to be overexpressed in diverse tumors, regulating target genes transcription associated with cancer development. Hence, LSD1 targeted inhibitors may represent a new insight in anticancer drug discovery. For these reasons, researchers in both the pharmaceutical industry and academia have been actively pursuing LSD1 inhibitors in the quest for new anti-cancer drugs.
OBJECTIVE: This
review summaries patents about LSD1 inhibitors in recent 5 years in hope of providing a reference for LSD1 researchers to develop new modulators of LSD1 with higher potency and fewer adverse effects.
METHODS: This
review collects LSD1 inhibitors disclosed in patents since 2016. The primary ways of patent searching are Espacenet®, Google Patents, and CNKI.
RESULTS: This
review covers dozens of patents related to LSD1 inhibitors in recent five years. The compound structures are mainly divided into TCP (
Tranylcypromine) derivatives, imidazole derivatives, pyrimidine derivatives, and other natural products and peptides. Meanwhile, the compounds that have entered the clinical phase are also described.
CONCLUSIONS: Most of the compounds in these patents have been subjected to activity analysis with LSD1 and multi-cell lines, showing good antitumor activity in vitro and in vivo. These patents exhibited the structural diversity of LSD1 inhibitors and the potential of natural products as novel LSD1 inhibitors.